The thyromimetic T-0681 protects from atherosclerosis.
J Lipid Res
; 50(5): 938-44, 2009 May.
Article
em En
| MEDLINE
| ID: mdl-19106072
ABSTRACT
This report describes studies in hyperlipidemic New Zealand White (NZW) rabbits investigating the impact of the liver-selective thyromimetic T-0681 on lipoprotein metabolism and the development of atherosclerosis. Prolonged treatment with T-0681 increased the hepatic expression of both LDL receptor and scavenger receptor class B, type I without affecting cholesteryl ester transfer protein activity. Upregulation of hepatic lipoprotein receptors was accompanied by a marked decrease of apolipoprotein B-containing lipoproteins, reflected by a 60% reduction of plasma cholesterol and a >70% reduction of plasma triglyceride levels. Most importantly, T-0681 reduced the development of atherosclerosis by 80% in NZW rabbits on high-cholesterol chow. Our data suggest that liver-selective thyromimetics, such as T-0681, may prove to be useful therapeutic agents against the development of atherosclerosis in humans.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Éteres Fenílicos
/
Aterosclerose
/
Malonatos
/
Anticolesterolemiantes
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article